Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AKINYEMI O AJAYI

Allopathic & Osteopathic Physicians Pediatrics Pediatric Pulmonology

NPI
1215915152
CMS profile
235840
Location
WINTER PARK, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$110,286.53

129 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AKINYEMI O AJAYI

NPI 1215915152 · CMS profile ID 235840

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Pulmonology

WINTER PARK, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215915152?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AKINYEMI O AJAYI, NPI 1215915152, CMS profile ID 235840. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215915152?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). AKINYEMI O AJAYI, NPI 1215915152, CMS profile ID 235840. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215915152?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
AKINYEMI O AJAYI, NPI 1215915152, CMS profile ID 235840, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1215915152?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

129 matching records · $110,286.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 129 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–129 of 129.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $187.1004/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404855 CMS
JAZZ PHARMACEUTICALS INC. $211.6804/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404251 CMS
Gilead Sciences, Inc. $107.8704/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025520929 CMS
JAZZ PHARMACEUTICALS INC. $94.0704/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404627 CMS
JAZZ PHARMACEUTICALS INC. $4,860.0004/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058401567 CMS
JAZZ PHARMACEUTICALS INC. $391.0504/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058402665 CMS
JAZZ PHARMACEUTICALS INC. $391.0504/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058402667 CMS
JAZZ PHARMACEUTICALS INC. $293.1503/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058401539 CMS
JAZZ PHARMACEUTICALS INC. $125.0103/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058401611 CMS
JAZZ PHARMACEUTICALS INC. $19.0003/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400785 CMS
JAZZ PHARMACEUTICALS INC. $98.0803/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400841 CMS
JAZZ PHARMACEUTICALS INC. $249.4203/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400927 CMS
JAZZ PHARMACEUTICALS INC. $761.4003/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404889 CMS
JAZZ PHARMACEUTICALS INC. $389.4603/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058401717 CMS
JAZZ PHARMACEUTICALS INC. $218.7003/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058401151 CMS
JAZZ PHARMACEUTICALS INC. $218.7003/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058401153 CMS
GENZYME CORPORATION $25.4303/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049930249 CMS
JAZZ PHARMACEUTICALS INC. $4,860.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400835 CMS
JAZZ PHARMACEUTICALS INC. $108.9802/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400889 CMS
Novartis Pharmaceuticals Corporation $13.9902/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991747879 CMS
GENZYME CORPORATION $101.2002/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049930237 CMS
JAZZ PHARMACEUTICALS INC. $25.0002/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400697 CMS
JAZZ PHARMACEUTICALS INC. $45.9102/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400851 CMS
JAZZ PHARMACEUTICALS INC. $4.0002/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400883 CMS
Regeneron Healthcare Solutions, Inc. $13.6502/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999070695 CMS
JAZZ PHARMACEUTICALS INC. $4,860.0001/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400825 CMS
JAZZ PHARMACEUTICALS INC. $148.4101/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400693 CMS
JAZZ PHARMACEUTICALS INC. $125.0001/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400929 CMS
JAZZ PHARMACEUTICALS INC. $627.9601/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400935 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $48,804.70 104
PY2020 $10,235.83 19
PY2021 $22,357.72 25
PY2022 $65,316.11 64
PY2023 $110,286.53 129
PY2024 $57,977.79 71
PY2025 $118,503.97 94

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $477,554.76 80
PY2024 Principal investigator $467,600.36 148
PY2023 Recipient $2,072.16 4
PY2023 Principal investigator $354,452.65 93
PY2022 Principal investigator $132,852.38 10
PY2021 Recipient $2,230.00 1
PY2020 Recipient $6,750.00 1
PY2020 Principal investigator $33,904.68 7
PY2019 Principal investigator $83,952.65 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

80 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $29,370.90 12/17/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEE
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223289836
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50.39 12/17/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEE
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223289838
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,097.51 12/11/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040413
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,560.00 12/01/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEE
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223288931
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,600.00 12/01/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEE
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223288933
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,560.00 12/01/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEE
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223288935
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $975.00 12/01/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEE
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223288937
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,860.00 12/01/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEE
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223288939
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,967.00 12/01/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEE
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223288941
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $90.00 12/01/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEE
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223288943
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $44.00 11/24/2025 Non-covered Recipient Entity
Florida Hospital for Children
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233739541
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $454.38 11/20/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040411
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,295.29 11/19/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223288523
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $28,482.00 11/12/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder No dispute reported 06/30/2026 1243532141
Principal investigator 1 Vanda Pharmaceuticals Inc. $6,500.00 10/17/2025 Non-covered Recipient Entity
FLORIDA PEDIATRIC RESEARCH INSTITUTE
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA No dispute reported 06/30/2026 1232946601
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $30,058.00 10/15/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEE
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223286987
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,636.10 10/15/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEE
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223286995
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,643.13 10/14/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040409
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $35,534.00 10/02/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder No dispute reported 06/30/2026 1243532137
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,513.02 09/24/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223285874
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $454.38 09/17/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040407
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 09/12/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192118311
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 09/12/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192118316
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,549.65 09/03/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223284929
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $90.00 09/01/2025 Non-covered Recipient Entity
Advarra, Inc.
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder No dispute reported 06/30/2026 1243525077
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 08/21/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737931
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,895.00 08/21/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737933
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $20,208.50 08/21/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737937
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $454.38 08/19/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040405
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24,948.30 08/06/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223283855
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $28,455.05 08/06/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223283871
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,577.94 07/25/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283194
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,643.13 07/24/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040403
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,067.00 07/14/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737935
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $46.80 07/11/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223282558
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $908.76 06/24/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040401
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.70 06/11/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737925
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.96 06/11/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737927
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.72 06/11/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737929
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $948.35 06/04/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223280622
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,925.00 05/23/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223280252
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,925.00 05/23/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS LLC
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223280276
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,659.90 05/14/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223279772
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $1,345.00 05/05/2025 Non-covered Recipient Entity
Advarra, Inc.
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder No dispute reported 06/30/2026 1243525082
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $156.71 05/02/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder No dispute reported 06/30/2026 1243532133
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,378.76 04/24/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040399
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $27,487.85 04/18/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223278478
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,925.00 04/18/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223278506
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,742.94 04/18/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223278522
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,500.00 04/11/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS LLC
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223277886
Principal investigator 1 GlaxoSmithKline, LLC. $6,773.18 04/09/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192118324
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,203.95 04/02/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223277562
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 03/21/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040291
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $90.00 03/17/2025 Non-covered Recipient Entity
Advarra, Inc.
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder No dispute reported 06/30/2026 1243525073
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,009.35 03/05/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223276065
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $230.10 03/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737913
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,299.20 03/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737923
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $908.76 02/27/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040397
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,355.41 02/26/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223275705
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,500.00 02/26/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223275711
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/21/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040461
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $128.70 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737887
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $128.70 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737889
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.30 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737891
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $210.60 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737893
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.30 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737895
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,258.40 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737897
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $128.70 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737899
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.30 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737901
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $724.36 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737903
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737905
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $128.70 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737907
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $128.70 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737909
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.30 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737911
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $128.70 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737915
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.30 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737917
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $210.60 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737919
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.30 02/03/2025 Non-covered Recipient Entity
Central Florida Pediatric Sleep Disorders Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737921
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $33,951.40 02/03/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223274709
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,461.25 01/30/2025 Non-covered Recipient Entity
CENTRAL FLORIDA PEDIATRIC SLEEP DISORDERS INSTITUTE
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040395